OPDUALAG FDA approval date

The FDA approved OPDUALAG on 18 Mar 2022.

FDA approval date
18 Mar 2022

Drug identity has not yet been verified against registry records

Also recorded as NIVOLUMAB; RELATLIMAB-RMBW

Included trials

No linked trials for this drug yet. Browse all trials

PDUFA dates and FDA decisions

Date as reportedDrug / companyEventConditionEvidence
2022-03-18DayOPDUALAGFDA original application approvalFDA approval decisionNot specifiedOpen original source
Read source excerpt

{"application_number": "BLA761234", "applicant_as_listed_by_fda": "BRISTOL MYERS SQUIBB", "brand_names": ["OPDUALAG"], "active_ingredients": ["NIVOLUMAB", "RELATLIMAB-RMBW"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20220318", "matched_on": "drug record created from this FDA brand name"}

First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026